Published 2 days ago • loading... • Updated 2 days ago

BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting

BrainXell Therapeutics is presenting data for BXT-110, an autologous iPSC-derived midbrain dopaminergic progenitor therapy, at the Society for Neuroscience Annual Meeting, San Diego on Nov. 15, 2025.
To showcase translational platforms, BrainXell highlighted scalable iPSC-derived cell models and a 3D neurovascular microfluidic blood–brain barrier model with tri-culture cells replicating barrier integrity.
Preclinical rodent studies demonstrated more than 75 percent FOXA2+/OTX2+ expression, over 60% TH+ neurons, greater than 60 percent graft survival, and significant behavioral recovery within 12 weeks, supporting BXT-110's disease-modifying potential.
The findings support BXT-110 as a promising disease-modifying therapy candidate for Parkinson's, emphasizing clinical translation platforms and leadership by Dr. Su‑Chun Zhang, MD, PhD, and BrainXell teams.
On Nov. 19th, BrainXell will present posters at locations #438.01, #401.06, and #369.23 during sessions at 1:00 p.m. and 8:00 a.m.

Insights by Ground AI

18 Articles

Montana Standard

+17 Reposted by 17 other sources

Center

BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting

SAN DIEGO, Nov. 15, 2025 /PRNewswire/ -- BrainXell, Inc. today announced that data will be presented during poster sessions at the 2025 Society for Neuroscience (SfN) Annual Meeting in San Diego, highlighting new breakthroughs in human iPSC-derived cell models and…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year